Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target
In this white paper, find out more about:
The structure and function of the RAS protein superfamily
The role and consequences of KRAS gene activation
How renowned companies are targeting KRAS in cancer therapies and what the current challenges in developing KRAS-targeted therapeutics are
How to identify novel KRAS inhibitors and how to characterize downstream KRAS signaling with Alpha Surefire®Ultra™ and HTRF® technologies
Download White Paper
We are committed to your privacy. Revvity needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our Privacy Policy.
